APSR2026-296

Yes
Regular
Submitted
Oral Presentation
AO06-006
 
 
 
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
13

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Sarah Yeo * Austin Health Department of Respiratory and Sleep Medicine Melbourne Australia
Paul Wang - Walter and Eliza Hall Institute of Medical Research Papenfuss Laboratory Melbourne Australia
Stephen Wong - Peter MacCallum Cancer Centre Cancer Genomics Translational Research Centre Melbourne Australia
Tony Papenfuss - Walter and Eliza Hall Institute of Medical Research Papenfuss Laboratory Melbourne Australia
Sagun Parakh - Austin Health Department of Oncology Melbourne Australia
Natasha Smallwood - Alfred Health Department of Respiratory and Sleep Medicine Melbourne Australia
Kate Sutherland - Walter and Eliza Hall Institute of Medical Research Cancer Biology and Stem Cells Division Melbourne Australia
Vivek Naranbhai - Alfred Health Department of Oncology Melbourne Australia
Daniel Steinfort - Royal Melbourne Hospiral Department of Respiratory and Sleep Medicine Melbourne Australia
Natalia Vukelic - La Trobe University Department of Microbiology, Anatomy, Physiology and Pharmacology Melbourne Australia
Farzaneh Atashrazm - Austin Health Department of Oncology Melbourne Australia
Sagun Parakh - Austin Health Department of Oncology Melbourne Australia
Tracy Leong - Austin Health Department of Respiratory and Sleep Medicine Melbourne Australia
-
-
Presenting Author Details
Sarah
Yeo
sarah.yeo@austin.org.au
+61403562332
31-40
Australia
Original Research
Feasibility and Clinical Utility of EBUS-Derived Whole Exome Sequencing for Predicting Immunotherapy Outcomes in Non-Small Cell Lung Cancer
Maximum 25 words
Abstract Content

Immunotherapy has improved survival in stage IV non-small cell lung cancer (NSCLC); however, primary and acquired resistance remain common and the underlying mechanisms are incompletely understood. Progress has been limited by difficulty obtaining sufficient, high-quality tumour tissue in advanced disease . Linear endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) offers minimally invasive tumour sampling and may provide material suitable for whole exome sequencing (WES). We evaluated the feasibility of WES from EBUS-TBNA specimens and explored genomic correlates of immunotherapy response.

Patients undergoing EBUS for suspected lung cancer were prospectively recruited through the TRACKER lung cancer biobank (2021-2025). EGFR- or ROS1- positive cases were excluded. Immunotherapy responders were defined as patients surviving ≥6 weeks and demonstrating radiological response after ≥6 months of chemoimmunotherapy. WES was performed using standard bioinformatic pipelines to identify somatic single nucleotide variants, small insertions/deletions, tumour mutational burden (TMB), and copy number alterations (CNAs). Genomic features were compared between responders and non-responders. 

Eighteen patients (21 EBUS-TBNA samples) were included ((mean age 66 years (range 47-81); 39% female). Nine were classified as responders, eight non-responders, and one had pending outcome data. WES was successful in all analysed samples.

Non-responders demonstrated a greater overall copy number burden, with a higher fraction of the genome affected by CNAs, particularly deletions. TMB was significantly higher in non-responders than responders (12.6 vs 5.6 mutations/Mb, p=0.0018). Distinct gene-level mutational patterns were observed between groups, though interpretation is limited by cohort size.

In this pilot cohort of advanced NSCLC, WES from EBUS-TBNA specimens was feasible and generated high-quality genomic data. Differences in copy number burden and mutational profiles between responders and non-responders warrant validation in larger studies to clarify genomic determinants of immunotherapy resistance.

 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
lung cancer, whole exome sequencing, immunotherapy resistance
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflicts of interest related to this work.
283